Physiological Barriers to Nucleic Acid Therapeutics and Engineering Strategies for Lipid Nanoparticle Design, Optimization, and Clinical Translation
Pharmaceutics · 08.10.2025 · 17 (10) · 1309
DOI: 10.3390/pharmaceutics17101309 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 08.10.2025. Verfasst von Yerim Kim und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Chemical Engineering and Bioengineering, College of Art, Culture and Engineering, Kangwon National University, Chuncheon-si 24341, Gangwo…. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 169 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, Ministry of Education (MOE) and the Gangwon State (G.S.).
Abstract (Originalsprache)
Lipid nanoparticles are a clinically validated platform for delivering nucleic acids, but performance is constrained by multiscale physiological barriers spanning circulation, vascular interfaces, extracellular matrices, cellular uptake, and intracellular trafficking. This review links composition–structure–function relationships for ionizable lipids, helper phospholipids, cholesterol, and PEG-lipids to systemic fate, endothelial access, endosomal escape, cytoplasmic stability, and nuclear transport. We outline strategies for tissue and cell targeting, including hepatocyte ligands, immune and tumor selectivity, and selective organ targeting through compositional tuning, together with approaches that modulate escape using pH-responsive chemistries or fusion-active peptides and polymers. We further examine immunomodulatory co-formulation, route and schedule effects on biodistribution and immune programming, and manufacturing and stability levers from microfluidic mixing to lyophilization. Across these themes, we weigh trade-offs between stealth and engagement, potency and tolerability, and potency and manufacturability, noting that only a small fraction of endosomes supports productive release and that protein corona variability and repeat dosing can reshape tropism and clearance. Convergence of standardized assays for true cytosolic delivery, biomarker-guided patient selection, and robust process controls will be required to extend LNP therapeutics beyond the liver while sustaining safety, access, and scale.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Chemical Engineering and Bioengineering, College of Art, Culture and Engineering, Kangwon National University, Chuncheon-si 24341, Gangwon-do, Republic of Korea.
- Institute of Fermentation of Brewing, Kangwon National University, Chuncheon-si 24341, Gangwon-do, Republic of Korea.
- Department of Smart Health Science and Technology, Kangwon National University, Chuncheon-si 24341, Gangwon-do, Republic of Korea.
- Department of Environmental Engineering, College of ACE, Kangwon National University, Chuncheon-si 24341, Gangwon-do, Republic of Korea.
ORCID-Profile: Jeong-Ann Park, Kwang Suk Lim, Suk-Jin Ha, Hyun-Ouk Kim
Förderung
- National Research Foundation of Korea
- Ministry of Education (MOE) and the Gangwon State (G.S.)
Zitieren
APA
Kim, Y., Park, J., Choi, J., Kim, M., Seo, G., Kim, J., Park, J. A., Lim, K. S., Ha, S. J., & Kim, H. O. (2025). Physiological Barriers to Nucleic Acid Therapeutics and Engineering Strategies for Lipid Nanoparticle Design, Optimization, and Clinical Translation. Pharmaceutics, 17(10), 1309. https://doi.org/10.3390/pharmaceutics17101309
Vancouver
Kim Y, Park J, Choi J, Kim M, Seo G, Kim J, et al. Physiological Barriers to Nucleic Acid Therapeutics and Engineering Strategies for Lipid Nanoparticle Design, Optimization, and Clinical Translation. Pharmaceutics. 2025;17(10):1309. doi:10.3390/pharmaceutics17101309
BibTeX
@article{Kim2025,
author = {Kim, Yerim and Park, Jisu and Choi, Jaewon and Kim, Minse and Seo, Gyeongsu and Kim, Jeongeun and Park, Jeong-Ann and Lim, Kwang Suk and Ha, Suk-Jin and Kim, Hyun-Ouk},
title = {Physiological Barriers to Nucleic Acid Therapeutics and Engineering Strategies for Lipid Nanoparticle Design, Optimization, and Clinical Translation},
journal = {Pharmaceutics},
year = {2025},
volume = {17},
number = {10},
pages = {1309},
doi = {10.3390/pharmaceutics17101309}
}
EUVIMED